Effects of Victoza (Liraglutide) Versus Lyxumia (Lixisenatide) on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

Trial Profile

Effects of Victoza (Liraglutide) Versus Lyxumia (Lixisenatide) on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 May 2017

At a glance

  • Drugs Liraglutide (Primary) ; Lixisenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 03 May 2017 Planned End Date changed from 1 Apr 2017 to 1 Jul 2017.
    • 03 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Jul 2017.
    • 01 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top